E-cadherin, N-cadherin, and calretinin in pleural effusions: The good, the bad, the worthless
- 5 March 1999
- journal article
- research article
- Published by Wiley in Diagnostic Cytopathology
- Vol. 20 (3) , 125-130
- https://doi.org/10.1002/(sici)1097-0339(199903)20:3<125::aid-dc3>3.0.co;2-v
Abstract
The distinction between reactive mesothelial cells (RMC), malignant mesothelioma (MM), and metastatic adenocarcinoma (ACA) in pleural effusions may be impossible based on morphology alone. E‐cadherin, N‐cadherin, and calretinin are newly described immunocytochemical markers which can potentially be utilized for facilitating this distinction. E‐cadherin and N‐cadherin are calcium‐dependent intercellular adhesion molecules expressed in epithelial cells and mesenchymal/mesothelial cells, respectively. The differential expression of E‐cadherins in epithelial cells and N‐cadherins in mesothelial cells has been utilized to differentiate reactive mesothelial cells, MMs and ACAs. Calretinin is a calcium‐binding protein within the family of EF‐hand proteins. It is abundantly expressed in peripheral and central nervous tissues, and has been shown to consistently immunoreact with mesothelial cells. We studied cell block sections from 77 pleural effusions (22 RMC, 26 MM, and 29 ACA) to investigate the potential immunocytochemical use of anti‐E‐cadherin, anti‐N‐cadherin, and anti‐calretinin antibodies for differentiating between RMC, MM, and ACA in pleural effusions. A modified avidin‐biotin peroxidase complex (ABC) method was used. E‐cadherin immunostaining was observed in 14% of RMC, 46% of MMs, and 97% of ACAs. A distinct membrane staining pattern was seen in ACAs. The pattern of staining was cytoplasmic in all reactive RMC and varied from membrane to cytoplasmic in MMs. Anti‐N‐cadherin immunoreacted with 77% of RMC, 35% of MMs, and 48% of ACAs. Twenty‐seven percent of RMC, 58% of MMs, and 31% of ACAs immunoreacted with anti‐calretinin. Based on these results, we conclude that anti‐E‐cadherin is a potentially useful marker in the distinction of ACA cells from RMC. However, it is not as useful for the distinction of ACA and MM. Anti‐N‐cadherin and anti‐calretinin did not reliably distinguish between reactive mesothelial, MM, and ACA cells in pleural effusions. Diagn. Cytopathol. 1999:20:125–130. Published 1999 Wiley‐Liss, Inc.Keywords
This publication has 19 references indexed in Scilit:
- Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytologyCancer, 1998
- The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluidsCancer, 1997
- The E-cadherin-mediated cell–cell adhesion system in human cancersBritish Journal of Surgery, 1997
- Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissuesHuman Pathology, 1997
- CalretininActa Cytologica, 1997
- Calretinin: A Novel Immunocytochemical Marker for MesotheliomaThe American Journal of Surgical Pathology, 1996
- The Calcium Binding Protein Calretinin is a Selective Marker for Malignant Pleural Mesotheliomas of the Epithelial TypePathology - Research and Practice, 1996
- The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomasHuman Pathology, 1995
- ME1-Antibody labelling of primary bronchogenic tumours and extrapulmonary malignanciesLung Cancer, 1994
- Calcium-binding proteins: selective markers of nerve cellsCell and tissue research, 1993